Diabetes drug trial offers hope for failing kidneys
NCT ID NCT05309785
Summary
This study is testing whether a diabetes medication called canagliflozin can safely reduce protein in the urine, a sign of kidney damage, in people with advanced kidney disease. It involves two small groups: people with very poor kidney function not yet on dialysis, and people already receiving dialysis. Researchers want to see if the drug works similarly in these patients as it does in people with healthier kidneys.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESRD are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
McGill University Health Center
Montreal, Quebec, Canada
Conditions
Explore the condition pages connected to this study.